Lung protease nanosensors and uses thereof
Aspects of the present disclosure relate to methods and compositions useful for in vivo and/or in vitro profiling of proteases present in the lung. In some embodiments, the disclosure provides methods of in vivo enzymatic processing of exogenous molecules followed by detection of detectable markers as representative of the presence of active proteases associated with a lung disease, for example, lung cancer and lung infections. In some embodiments, the disclosure provides compositions and methods for production of a lung disease signature and diagnosis of lung disease.
1. A method comprising
detecting a detectable marker in a blood sample or urine sample obtained from a subject that has been administered to the lung of the subject by inhalation or intratracheal administration a lung protease nanosensor comprising:
(a) (i) a multi-arm polyethylene glycol molecule (multi-arm PEG) scaffold and/or (ii) a polyethylene glycol (PEG) scaffold with a molecular weight equal to or greater than 40 kDa; linked to
(b) a substrate,
wherein the substrate is conjugated to a detectable marker,
wherein the detectable marker is released from the nanosensor when exposed to a protease present in a lung, and
wherein the subject has or is suspected of having lung cancer.
2. The method of 1 , wherein the lung protease nanosensor is delivered to the lung using an aerosol delivery device which is not reliant on propellant or compressed air.
3. The method of claim 1 , wherein the substrate comprises a sequence selected from the group consisting of SEQ ID NOs: 1-14.
4. The method of claim 1 , wherein the lung protease nanosensor comprises the scaffold linked to a plurality of substrates, wherein each substrate is conjugated to a detectable marker, whereby the detectable marker is capable of being released from the nanosensor when exposed to a protease present in a lung.
5. The method of claim 1 , wherein the scaffold is greater than 5 nm in size.
6. The method of claim 1 , wherein the detectable marker is less than 3 nm in size.
7. The method of claim 1 , wherein the lung protease nanosensor comprises the multi-arm PEG scaffold.
8. The method of claim 1 , wherein the subject is administered a composition comprising at least two lung protease nanosensors.
9. The method of claim 8 , wherein the substrate of each lung protease nanosensor is independently selected from the group consisting of a substrate that is capable of being cleaved by ACE2, CTSD, F7, KLK13, KLK14, KLK6, MMP1, MMP11, MMP12, MMP13, MMP3, NAPSA, PRSS22, PRSS3, PRSS8, and combinations thereof.
10. The method of claim 1 , wherein inhalation comprises dry powder inhalation and/or nebulization of the lung protease nanosensor.
11. The method of claim 1 , wherein the detectable marker comprises a peptide.
12. A method for classifying lung disease in a subject, the method comprising:
(i) detecting in a biological sample obtained from a subject that has been administered one or more lung protease nanosensors, wherein the one or more lung protease nanosensors have been administered to the lung of the subject by inhalation or intratracheal administration: one or more detectable markers that have been released from the one or more lung protease nanosensors when exposed to an enzyme present in the lung of the subject, wherein each of the one or more lung protease nanosensors comprises:
(a) (1) a multi-arm polyethylene glycol molecule (multi-arm PEG) scaffold and/or (2) a polyethylene glycol (PEG) scaffold with a molecular weight equal to or greater than 40 kDa; linked to
(b) a substrate,
wherein the substrate is conjugated to a detectable marker,
wherein the detectable marker is released from the nanosensor when exposed to a protease present in a lung, and
wherein the biological sample is a blood sample or urine sample; and
(ii) classifying the subject as having a type of lung disease based on the identity of the detectable markers present in the biological sample, wherein the presence of the detectable markers in the biological sample is indicative of one or more cancer-associated enzymes being present in an active form within the lung of the subject.
13. A method of treating lung cancer in a subject, the method comprising administering a therapeutic agent for treatment of lung cancer to or performing a therapeutic intervention on a subject who has been classified as having lung cancer according to the method of claim 12 .
14. A method comprising:
(a) administering to the lung of a subject, by inhalation or intratracheal administration, a lung protease nanosensor comprising:
(i) (1) a multi-arm polyethylene glycol molecule (multi-arm PEG) scaffold and/or (2) a polyethylene glycol (PEG) scaffold with a molecular weight equal to or greater than 40 kDa; linked to
(ii) a lung infection substrate,
wherein the substrate is conjugated to a detectable marker,
wherein the substrate includes a detectable marker,
whereby the detectable marker is released from the lung protease nanosensor when exposed to a protease present in the lung, and
wherein the subject has or is suspected of having a lung infection; and
(b) detecting and quantifying the detectable marker from a blood sample or a urine sample from the subject.
15. The method of claim 14 , wherein the subject has been administered an antibiotic.
16. The method of claim 15 , wherein the antibiotic has been administered prior to (a) or (b).
17. The method of claim 14 , wherein the lung infection is a Pseudomonas aeruginosa infection.
18. The method of claim 14 , wherein the protease is a pathogen protease.
19. The method of claim 14 , wherein the biological sample is urine.
20. The method of claim 14 , wherein the lung protease nanosensor comprises the multi-arm PEG scaffold.